According to brokerages, Lupin’s growth outlook for FY25 and FY26 looks more promising, as the company company has strong launches lined up with drugs such as Slynd, Doxil, PredForte, Liraglutide, ...

It is sold as Spiriva HandiHaler, a dry powder inhaler approved in 2004, or as Spiriva Respimat, an inhalation spray approved in 2014. The Phase 4 trial — a type of study conducted after a medication ...

You may be able to get a 90-day supply of Spiriva if approved by your insurance company. This could reduce your number of trips to the pharmacy and help lower the cost of the drug.

Verona Pharma (NASDAQ: VRNA) is a biopharmaceutical company based in London with offices in the US. VRNA´s main candidate drug is ensifentrine, a promising treatment for patients suffering from ...

The company launched one of its products named Spiriva Respimat, an inhaler using AR. The innovative demonstration session used 3D animations and gesture-based controls to exhibit how the product ...

Spiriva HandiHaler was approved by the FDA in 2004 as a COPD maintenance treatment and in 2009 to reduce COPD exacerbations. Like the approved generic, it is not intended as a rescue medication for ...

Analysts of IIFL Capital Services expect Spiriva to generate sales of USD100-130mn p.a., over FY24-26, assuming HandiHaler market size of USD600mn, Lupin’s MS of 20-25% and price erosion of 10-20%.

Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

Shares of Lupin Ltd. pared some gains on Thursday after hitting a 52-week high the previous day following the announcement of the approval of the company's generic version of Spiriva. The drug is used ...

Mumbai: Global pharma major Lupin Limited has announced that the company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application ...

Lupin ’s shares declined 4.5 per cent in Thursday’s intra-day trade as analysts believe the stock's expensive valuations may cap gains arising from the approval for inhalation drug Spiriva (Tiotropium ...